• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Ultragenyx Pharmaceutical (RARE)

Common Shares
Sell: $37.40|Buy: $39.90|Change: 0.91 (2.39%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Address

60 Leveroni Court
Novato
CA
USA
94949

Telephone

+1 415 4838800

Website

https://www.ultragenyx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Ultragenyx Pharmaceutical Inc Annual Report for 20252026-02-19T00:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 20252026-02-13T17:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Results for 20252026-02-13T00:00:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Conference Call for 20252025-11-05T17:00:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Results for 20252025-11-05T00:00:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Conference Call for 20252025-08-01T17:00:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Results for 20252025-08-01T00:00:00
Ultragenyx Pharmaceutical Inc Annual General Meeting for 20252025-06-18T09:30:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call for 20252025-05-02T17:00:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Results for 20252025-05-02T00:00:00

Previous key dates

NameKey Date
Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call for 20252025-05-02T17:00:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Results for 20252025-05-02T00:00:00
Leerink Partners Global Biopharma Conference2025-03-12T13:40:00
Barclays 27th Annual Global Healthcare Conference2025-03-11T13:00:00
45th Annual Cowen Healthcare Conference2025-03-03T11:10:00
Ultragenyx Pharmaceutical Inc Annual Report for 20242025-02-19T00:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 20242025-02-13T17:00:00
Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Result for 20242025-02-13T00:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-13T10:30:00
Piper Sandler’s 36th Annual Healthcare Conference2024-12-05T09:00:00
7th Annual Evercore ISI HealthCONx Conference2024-12-04T09:10:00
Citi’s 2024 Global Healthcare Conference2024-12-03T13:45:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Conference Call for 20242024-11-05T17:00:00
Ultragenyx Pharmaceutical Inc Third Quarter Earnings Result for 20242024-11-05T00:00:00
Bank of America Global Healthcare Conference2024-09-18T15:05:00
Cantor Global Healthcare Conference2024-09-17T13:20:00
Morgan Stanley 22nd Annual Global Healthcare Conference2024-09-04T14:35:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Conference Call for 20242024-08-01T17:00:00
Ultragenyx Pharmaceutical Inc Second Quarter Earnings Result for 20242024-08-01T00:00:00
Ultragenyx Pharmaceutical Inc Annual General Meeting for 20242024-06-18T09:30:00
Goldman Sachs 45th Annual Global Healthcare Conference 20242024-06-11T10:00:00
Goldman Sachs 45th Annual Global Healthcare Conference2024-06-11T10:00:00
Ultragenyx Pharmaceutical Inc to discuss the topline data from the DTX401 Phase 3 GlucoGene study2024-05-30T17:00:00
Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference2024-05-14T13:40:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call for 20242024-05-02T17:00:00
Ultragenyx Pharmaceutical Inc First Quarter Earnings Result for 20242024-05-02T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.